BCAL Diagnostics (ASX:BDX) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Days Payable?

BCAL Diagnostics's average Accounts Payable for the six months ended in Dec. 2023 was A$1.18 Mil. BCAL Diagnostics's Cost of Goods Sold for the six months ended in Dec. 2023 was A$0.00 Mil.

The historical rank and industry rank for BCAL Diagnostics's Days Payable or its related term are showing as below:

ASX:BDX's Days Payable is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 66.645
* Ranked among companies with meaningful Days Payable only.

BCAL Diagnostics's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

BCAL Diagnostics Days Payable Historical Data

The historical data trend for BCAL Diagnostics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Days Payable Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

Days Payable

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Days Payable	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of BCAL Diagnostics's Days Payable

For the Diagnostics & Research subindustry, BCAL Diagnostics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BCAL Diagnostics's Days Payable Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Days Payable distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's Days Payable falls into.

BCAL Diagnostics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

BCAL Diagnostics's Days Payable for the fiscal year that ended in Jun. 2023 is calculated as

	Days Payable (A: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2022 )	+	Accounts Payable (A: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2023 )	*	Days in Period
=	( (0.277	+	1.581)	/	2 )	/	0	*	365
=	0.929					/	0	*	365
=	N/A

BCAL Diagnostics's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (1.581	+	0.769)	/	2 )	/	0	*	365 / 2
=	1.175					/	0	*	365 / 2
=	N/A

BCAL Diagnostics Days Payable Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.